FM
fazen.markets
healthcare·esfritzh

FDA Rejects Summit's Ivonescimab BLA on Overall Survival

3h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

summit-therapeuticsivonescimabfda-complete-response-lettersmmt-stockpd-1-vegf-bispecific
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1The FDA has declined to approve ivonescimab on progression-free survival alone, leaving overall survival as the bar Summit must now clear.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Summit Therapeutics Inc. (NASDAQ: SMMT) disclosed on 15 November 2026 that the U.S. Food and Drug Administration issued a Complete Response Letter for the Biologics License Application covering ivonescimab plus platinum-containing chemotherapy in previously treated EGFR-mutated non-small cell lung cancer. The agency told the company that substantial evidence of effectiveness was not established without a statistically significant overall survival benefit. HARMONi, the supporting Phase III trial, met its progression-free survival primary endpoint but missed statistical significance on overall survival. The FDA concluded that the PFS benefit alone did not support a positive benefit-risk profile.

Context — Why the Ivonescimab CRL Matters Now

The FDA's objection is narrow and specific. It is not a safety rejection. The company reported that ivonescimab plus chemotherapy was well tolerated, with no new safety signals and comparable rates of discontinuation and death between the two arms.

Instead, the agency drew a line on the strength of evidence. In the primary overall survival analysis, ivonescimab plus chemotherapy showed a positive trend without statistical significance. The FDA said a PFS benefit without a statistically significant OS benefit does not support approval in this setting.

The company noted that no FDA-approved regimen has demonstrated a statistically significant OS benefit in this patient population. That is a structural fact about the indication, not a defence of the application, and it frames how unusual the agency's bar is here.

Summit's case rests on post-hoc data. In longer-term follow-up of western patients, the company said a consistent OS benefit appeared across regions, with a hazard ratio of 0.76 in the full population, in Asian patients, and in western patients. Post-hoc analyses are not prespecified endpoints, and the FDA did not accept them as the basis for approval.

The catalyst chain is therefore straightforward: HARMONi met PFS, missed OS, and the agency declined to approve on PFS alone. Summit had framed the regimen as an option for patients who had exhausted existing therapies. The FDA disagreed that the evidence supported that option in its present form.

Data — What the Numbers Show

The HARMONi trial was global, randomized and double-blind. It compared ivonescimab plus platinum-containing chemotherapy against placebo plus platinum-containing chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC previously treated with a third-generation EGFR TKI.

The study had two primary endpoints, PFS and OS. Summit said HARMONi met the PFS primary endpoint and became the first global Phase III study of an immunotherapy-based regimen to show a statistically significant PFS improvement in this setting. The OS primary endpoint did not reach statistical significance.

MeasureResult
Primary PFS endpointMet, statistically significant
Primary OS endpointPositive trend, not statistically significant
Post-hoc OS hazard ratio0.76 (full population, Asian, western)
Discontinuation due to TRAEs16 patients (7.3%) ivonescimab vs 11 (5.0%) placebo
Deaths from TRAEs4 patients (1.8%) vs 5 patients (2.3%)

Safety figures were closely matched. Discontinuations from treatment-related adverse events ran slightly higher on the ivonescimab arm, while deaths attributed to TRAEs ran marginally higher on the chemotherapy-alone arm. Neither difference was flagged by the company as a new signal.

The company also said more than 5,000 patients have been treated with ivonescimab in clinical studies globally, and more than 100,000 when commercial use in China is included, as noted by Akeso. Ivonescimab was first approved for marketing authorisation in China in May 2024. No PD-1 x VEGF bispecific antibody is approved in the United States.

Analysis — What It Means for Healthcare and Biotech

The read-through lands on the bispecific antibody class rather than on Summit alone. Ivonescimab pairs PD-1 blockade with VEGF blockade in one molecule, designed for cooperative binding that favours tumour tissue. Summit licenses the asset for North America, South America, Europe, the Middle East, Africa and Japan, while Akeso holds rights elsewhere.

The company's counter-argument is breadth. Summit said it now has five positive Phase III studies between itself and Akeso, and that the CRL does not change its view of the opportunity. That claim rests on the company's own definition of a positive study, which it describes as one where a prespecified primary endpoint achieves a statistically significant benefit. A study can meet that definition on PFS while failing on OS, which is exactly the HARMONi outcome.

The limitation is that a CRL in one indication does not read across to the rest of the programme. HARMONi-3, HARMONi-7, HARMONi-GI3, HARMONi-GU1 and SMT112-216 test different settings, lines of therapy and combinations. Each carries its own endpoint structure and its own regulatory risk.

Partner exposure matters too. Summit is collaborating with AstraZeneca and Daiichi Sankyo on combinations with datopotamab deruxtecan, with AstraZeneca on sonesitatug vedotin, with Revolution Medicines on RAS(ON) inhibitors, with GSK on risvutatug rezetecan, and with Arcus Biosciences on casdatifan. Two cooperative groups, GORTEC and ECOG-ACRIN, are running or planning Phase III work in head and neck and biliary tract cancer.

Positioning in a name like this typically turns on the next data readout rather than the last one. A CRL removes a near-term approval catalyst and shifts attention to the company's multiregional trial programme and to any regulatory interaction that follows.

Outlook — What to Watch Next

The company did not disclose whether it intends to appeal, resubmit, or request a meeting with the FDA. It also did not give a timeline for any further regulatory submission for this indication.

The near-term catalysts are the ongoing trials. HARMONi-3 tests first-line metastatic NSCLC in two separately analysed cohorts, squamous and non-squamous. HARMONi-7 tests monotherapy in first-line metastatic NSCLC with high PD-L1 expression. HARMONi-GI3 covers first-line unresectable metastatic colorectal cancer.

The ILLUMINE study, GORTEC 2024-04, carries the identifier NCT07264075 and is sponsored by GORTEC, with intended conduct across multiple European countries and China. Summit said it may consider expanding that study into the United States.

Summit did not provide enrolment completion dates or data-readout windows for any of these programmes, so timing on the next binary event is not established. The report gives no share price levels or moving averages to anchor a technical view.

Frequently Asked Questions

What is a Complete Response Letter from the FDA?

A Complete Response Letter is the agency's formal notice that an application cannot be approved in its current form. It is not a rejection of the drug outright and not a safety finding. In this case the FDA said substantial evidence of effectiveness was not established without a statistically significant overall survival benefit, and that a progression-free survival benefit alone did not support a positive benefit-risk profile.

What does the CRL mean for Summit Therapeutics shareholders?

It removes the near-term U.S. approval catalyst for this specific regimen in previously treated EGFR-mutated NSCLC. Summit said the outcome does not change its belief in ivonescimab or its development plans, citing five positive Phase III studies across its work with Akeso. The company has not disclosed its next regulatory step or a revised timeline.

Is ivonescimab approved anywhere else?

Ivonescimab is not approved by any regulatory authority in Summit's licence territories, which cover North America, South America, Europe, the Middle East, Africa and Japan. It was initially approved for marketing authorisation in China in May 2024, where it is developed by Akeso Inc. and known as AK112. No PD-1 x VEGF bispecific antibody is currently approved in the United States.

Bottom Line

The FDA has declined to approve ivonescimab on progression-free survival alone, leaving overall survival as the bar Summit must now clear.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related